Everything below concerns Angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
For example, in biochemistry it is widely used to separate charged molecules such as proteins. An important area of the application is extraction and purification of biologically produced substances such as proteins (amino acids) and DNA/RNA. Ion-exchange processes are used to separate and purify metals, including separating uranium from plutonium and the other actinides, including thorium, neptunium, and americium. This process is also used to separate the lanthanides, such as lanthanum, cerium, neodymium, praseodymium, europium, and ytterbium, from each other. The separation of neodymium and praseodymium was a particularly difficult one, and those were formerly thought to be just one element didymium – but that is an alloy of the two. There are two series of rare-earth metals, the lanthanides and the actinides, both of whose families all have very similar chemical and physical properties. Using methods developed by Frank Spedding in the 1940s, ion-exchange processes were formerly the only practical way to separate them in large quantities, until the development of the "solvent extraction" techniques that can be scaled up enormously. A very important case of ion-exchange is the plutonium-uranium extraction process (PUREX), which is used to separate the plutonium (mainly [[plutonium-239|239Pu) and the uranium (in that case known as reprocessed uranium) contained in spent fuel from americium, curium, neptunium (the minor actinides), and the fission products that come from nuclear reactors. Thus the waste products can be separated out for disposal.
In petroleum engineering, in situ techniques involve the application of heat or solvents to extract heavy crude oil or bitumen from reservoirs located beneath the Earth's surface. Several in situ methods exist, but those that utilize heat, particularly steam, have proven to be the most effective for oil sands extraction. The most widely used in situ technique is steam-assisted gravity drainage (SAGD). This method employs two horizontal wells: the upper well injects steam to heat the bitumen, reducing its viscosity, while the lower well collects the mobilized oil for extraction. SAGD has gained prominence in the Canadian province of Alberta, due to its efficiency in recovering bitumen from deep reservoirs. Approximately 80% of Alberta's oil sands deposits are located at depths that render open-pit mining impractical, making in situ techniques such as SAGD the primary method of extraction.
=== Alcohol === Alcohol gains access to the central nervous system by entering the blood stream through the lining of the stomach and small intestine. Subsequently, it transverses the blood brain barrier via the circulatory system. The absorbed alcohol can diminish reflexes, disrupt nerve impulses, prolong muscle responses, and impact various other physiological functions throughout the body.
Sources: en.wikipedia.org
== Signs and symptoms == Acrocyanosis is characterized by peripheral cyanosis: persistent cyanosis of the hands, feet, knees, or face. The extremities often are cold and clammy and may exhibit some swelling (especially in warmer weather). The palms and soles exhibit a wide range of sweating from moderately moist to profuse, but all peripheral pulses should have normal rate, rhythm, and quality. Exposure to cold temperatures worsens the cyanosis, while it often improves on warming. Aside from the color changes, patients normally are asymptomatic and therefore there is usually no associated pain. The most common sign, discoloration, usually is what prompts patients to seek medical care.
== Etymology == William C. Boyd alone and then together with Elizabeth Shapleigh introduced the term "lectin" in 1954 from the Latin word lectus, "chosen" (from the verb legere, to choose or pick out).
Examples of drugs that can raise the serum potassium are non-selective beta-blockers such as propranolol and labetalol. Beta-1 selective blockers such as metoprolol do not increase serum potassium levels. Exercise can cause a release of potassium into the bloodstream by increasing the number of potassium channels in the cell membrane. The degree of potassium elevation varies with the degree of exercise, which ranges from 0.3 meq/L in light exercise to 2 meq/L in heavy exercise, with or without accompanying ECG changes or lactic acidosis. However, peak potassium levels can be reduced by prior physical conditioning, and potassium levels are usually reversed several minutes after exercise. High levels of adrenaline and noradrenaline have a protective effect on the cardiac electrophysiology because they bind to beta 2 adrenergic receptors, which, when activated, extracellularly decrease potassium concentration. Hyperkalemic periodic paralysis is an autosomal dominant clinical condition where there is a mutation in the gene located at 17q23 that regulates the production of protein SCN4A. SCN4A is an important component of sodium channels in skeletal muscles. During exercise, sodium channels normally open to allow the influx of sodium into the muscle cells for depolarization to occur. But in hyperkalemic periodic paralysis, sodium channels are slow to close after exercise, causing excessive influx of sodium and displacement of potassium out of the cells. Rare causes of hyperkalemia are discussed as follows.
Sources: en.wikipedia.org
== Chemical modification of amino acids == citrullination, or deimination, the conversion of arginine to citrulline deamidation, the conversion of glutamine to glutamic acid or asparagine to aspartic acid eliminylation, the conversion to an alkene by beta-elimination of phosphothreonine and phosphoserine, or dehydration of threonine and serine
=== Other anabolic agents === Clenbuterol – a beta-agonist; anabolic ability dubious Selective androgen receptor modulators (SARMs) Tibolone – a synthetic steroid Zeranol – a nonsteroidal estrogen Zilpaterol – a beta2-agnoist; anabolic ability dubious
Anguilla - The Scout Association of Anguilla Bermuda - Bermuda Scout Association Cayman Islands - The Scout Association of the Cayman Islands Falkland Islands - Scouting and Guiding in the Falkland Islands Gibraltar - The Scout Association of Gibraltar Montserrat - The Scout Association of Montserrat Saint Helena and Ascension Island - Scouting and Guiding on Saint Helena and Ascension Island Turks and Caicos Islands - The Scout Association of the Turks and Caicos British Virgin Islands - The Scout Association of the British Virgin Islands United States
Neuroanatomical studies support that autism may involve abnormal neuronal growth and pruning, leading to brain enlargement in some areas and reduction in others. Functional neuroimaging studies show reduced activation in somatosensory cortices during theory of mind tasks in autistic individuals and highlight potential imbalances in neurotransmitters like glutamate and Γ-aminobutyric acid that may underlie autism's behavioural manifestations.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.